Intratympanic Gene Delivery of Antimicrobial Molecules in Otitis Media

Area of Science:

• Otolaryngology
• Gene Therapy
• Microbiology

Background:

• Otitis media (OM) is a common childhood infection impacting development and frequently treated with antibiotics.
• Emerging antibiotic resistance and pathogen shifts necessitate novel non-antibiotic treatments for OM.
• The middle ear epithelium produces antimicrobial peptides that can combat common OM pathogens.

Purpose of the Study:

• To investigate the potential of gene therapy with beta-defensin 2 as a non-antibiotic treatment for otitis media.
• To evaluate the efficacy of adenovirus-mediated gene delivery of beta-defensin 2 to middle ear epithelial cells.

Main Methods:

• Adenoviral vector used for gene delivery of beta-defensin 2 to middle ear epithelial cells.
• In vitro and in vivo studies conducted to assess gene delivery and therapeutic effects.
• Experimental otitis media models used to evaluate protective efficacy.

Main Results:

• Adenoviral vector successfully delivered the beta-defensin 2 gene to middle ear epithelial cells in vitro and in vivo.
• Adenovirus-mediated overexpression of beta-defensin 2 demonstrated protective effects against experimental otitis media.
• Demonstrated feasibility of gene delivery to the middle ear epithelium.

Conclusions:

• Intratympanic gene therapy with beta-defensin 2 is a viable alternative or adjuvant strategy for otitis media management.
• Beta-defensin 2 gene therapy shows promise in overcoming challenges of respiratory tract gene delivery.
• This approach offers a novel non-antibiotic treatment option for pediatric otitis media.